| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-08-17 | Basilea Pharmaceutica (Switzerland) Hikma Pharmaceuticals (UK) | Zevtera® (ceftobiprole medocaril) Cresemba® (isavuconazole) | severe community-acquired and hospital-acquired pneumonia, invasive aspergillosis, mucormycosis | licensing - distribution | Infectious diseases | Distribution agreement |
| 2016-08-17 | Medivir (Sweden) Trek Therapeutics (USA - MA) | MIV-802 | hepatitis C | licensing - development - commercialisation | Infectious diseases | Licensing agreement |
| 2016-08-16 | Avacta (UK) | opening of new premises |
Diagnostic | Opening of new premises | ||
| 2016-08-16 | Inovio Pharmaceuticals (USA - PA) Plumbline Life Sciences (Republic of Korea) | DNA vaccine. | veterinary vaccine for foot and mouth disease | licensing | Veterinary medicine | Licensing agreement |
| 2016-08-16 | Recordati (Italy) | nomination | Nomination | |||
| 2016-08-12 | Probiodrug (Germany) | nomination resignation |
Neurodegenerative diseases | Nomination | ||
| 2016-08-11 | Jacobs Engineering Group (USA - CA) Novartis (Switzerland) | Novartis Biotechnology Center in Huningue, France | construction of new premises services contract |
Technology - Services | Construction of new premises | |
| 2016-08-11 | Marken (USA) | opening of new premises |
Technology - Services | Opening of new premises | ||
| 2016-08-11 | Cempra (USA - NC) | nomination |
Infectious diseases | Nomination | ||
| 2016-08-11 | BiolineRx (Israel) | Nomination | ||||
| 2016-08-10 | Nicox (France) GHO Capital (UK) | restructuring |
Ophtalmological diseases | Restructuring | ||
| 2016-08-10 | Kuros Biosciences (Switzerland) | nomination |
Regenerative Medicine | Nomination | ||
| 2016-08-10 | Genmab (Denmark) Gilead Sciences (USA - CA) | DuoBody® technology platform to develop bispecific antibody candidates for a therapeutic program targeting HIV | HIV infection | licensing |
Infectious diseases | Licensing agreement |
| 2016-08-10 | Gilead Sciences (USA - CA) Polyphor (Switzerland) | macrocycle molecules addressing biological targets selected by Gilead | undisclosed | licensing collaboration |
undisclosed | Licensing agreement |
| 2016-08-09 | Pharming (The Netherlands) Salix Pharmaceuticals (USA - NC) Valeant Pharmaceuticals (Canada) | Ruconest® - Rhucin® in non-European territories (conestat alfa - recombinant human C1 inhibitor) | acute attacks of Hereditary Angioedema (HAE) | commercialisation |
Rare diseases - Genetic diseases | Commercialisation agreement |
| 2016-08-09 | Abeona Therapeutics (USA - NY) EB Research Partnership (EBRP) (USA - NY) EB Research Medical Foundation (EBMRF) (USA - CA) | gene therapy treatments | epidermolysis bullosa | collaboration |
Rare diseases - Genetic diseases - Dermatological diseases | Collaboration agreement |
| 2016-08-09 | Selvita (Poland) University of California, San Francisco (UCSF) (USA - CA) | small molecules for the treatment of neurodegenerative diseases | neurodegenerative diseases | collaboration - services contract | Neurodegenerative diseases | Services contract |
| 2016-08-08 | Hospira (USA - IL) Pfenex (USA - CA) | PF582 ( biosimilar candidate to Lucentis® - ranibizumab injection) | wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), visual impairment due to macular edema secondary to retinal vein occlusion (RVO) | development commercialisation |
Ophtalmological diseases | Termination of an agreement |
| 2016-08-08 | Helsinn Group (Switzerland) MEI Pharma (USA - CA) | pracinostat | acute myeloid leukemia and other potential indications including myelodysplastic syndrome | licensing development commercialisation |
Cancer - Oncology | Licensing agreement |
| 2016-08-04 | Juno Therapeutics (USA - WA) Memorial Sloan Kettering Cancer Center (USA - NY) Eureka Therapeutics (USA - CA) | fully-human binding domain targeting B-cell maturation antigen (BCMA) and binding domains against two additional undisclosed multiple myeloma targets | multiple myeloma | licensing | Cancer - Oncology | Licensing agreement |
